Eli Lilly

LLY

Market cap $686B

Overview Fund Activity

765.18 USD

+5.05

0.66%

At close Updated Sep 18, 10:50 AM EDT

1 day

0.66%

5 days

0.66%

1 month

9.62%

3 months

-2.53%

6 months

-6.97%

Year to date

-1.66%

1 year

-15.45%

5 years

396.32%

10 years

764.71%

About: Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.

Employees: 47,000

Healthcare Drug Manufacturers - General

0

Funds holding %

of 7,463 funds

0

Analysts bullish %

of 8 analysts

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

32% more call options, than puts

Call options by funds: $14.1B | Put options by funds: $10.7B

25% more first-time investments, than exits

New positions opened: 217 | Existing positions closed: 173

21% more repeat investments, than reductions

Existing positions increased: 1,737 | Existing positions reduced: 1,432

1% less funds holding

Funds holding: 3,871 [Q1] → 3,841 (-30) [Q2]

3.22% less ownership

Funds ownership: 86.82% [Q1] → 83.6% (-3.22%) [Q2]

10% less capital invested

Capital invested by funds: $678B [Q1] → $608B (-$70.3B) [Q2]

26% less funds holding in top 10

Funds holding in top 10: 388 [Q1] → 286 (-102) [Q2]

See Fund Rankings

Research analyst outlook

8 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$700

9% downside

Avg. target

$901

18% upside

High target

$1,135

48% upside

8 analyst ratings

6 positive

75%

2 neutral

25%

0 negative

0%

Berenberg Kerry Holford	$830	Hold Downgraded	17 Sep 2025
JP Morgan Chris Schott	$1,050	Overweight Maintained	16 Sep 2025
HSBC Rajesh Kumar	$700	Hold Upgraded	27 Aug 2025
Guggenheim Seamus Fernandez	$875	Buy Maintained	13 Aug 2025
Cantor Fitzgerald Carter Gould	$825	Overweight Maintained	13 Aug 2025
Deutsche Bank James Shin	$900	Buy Maintained	11 Aug 2025
UBS Trung Huynh	$895	Buy Maintained	8 Aug 2025
Morgan Stanley Terence Flynn	$1,135	Overweight Maintained	10 Jul 2025

See Analyst Rankings

Financial journalist opinion

Based on 159 articles about LLY published over the past 30 days

Novo Nordisk's Wegovy Outperforms Eli Lilly's Tirzepatide In Reducing Risk Of Heart Attack, Stroke, And Death: Study

Novo Nordisk A/S NVO presented data from the STEER real-world study of evidence gathered from actual patient experiences at the European Society of Cardiology (ESC) Congress 2025.

Novo Nordisk's Wegovy Outperforms Eli Lilly's Tirzepatide In Reducing Risk Of Heart Attack, Stroke, And Death: Study

Novo Nordisk Stock Jumps. New Ozempic Data for Seniors Beats Rival Eli Lilly Medicine.

In a study with people with Type 2 diabetes and cardiovascular disease, the drug Ozempic was shown to reduce the risk of heart attack, stroke and death by 23% compared with an older drug.

Novo Nordisk Stock Jumps. New Ozempic Data for Seniors Beats Rival Eli Lilly Medicine.

The Motley Fool

3 Dividend Growth Stocks You Can Buy and Forget About

If you want a good dividend growth stock to buy and not worry about, look no further. The three stocks that I've listed here have tremendous long-term growth prospects, offer great dividends, and have been increasing their payouts for years.

3 Dividend Growth Stocks You Can Buy and Forget About

CNBC Television

Market delayed in reaction to Novo Nordisk and Eli Lilly' s GLP-1 pills, says Mizuho's Jared Holz

Jared Holz, Mizuho, joins 'Fast Money' to talk competition in the GLP-1 pill space between Novo Nordisk and Eli Lilly.

Market delayed in reaction to Novo Nordisk and Eli Lilly' s GLP-1 pills, says Mizuho's Jared Holz

Lilly's Mounjaro helps improve blood sugar control in children in late-stage trial

Eli Lilly's Mounjaro helped children and adolescents aged 10 to 17 years with type 2 diabetes manage their blood sugar better and lose weight, according to trial results presented at a medical meeting on Wednesday.

Lilly's Mounjaro helps improve blood sugar control in children in late-stage trial

Lilly's Mounjaro (tirzepatide), a GIP/GLP-1 dual receptor agonist, reduced A1C by an average of 2.2% in a Phase 3 trial of children and adolescents with type 2 diabetes

In SURPASS-PEDS, Mounjaro met the primary and all key secondary endpoints at 30 weeks and showed sustained improvement in glycemic control and continued BMI reduction through the study's 52-week extension The safety and tolerability profile of Mounjaro was generally consistent with previous adult studies INDIANAPOLIS , Sept. 17, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced detailed results from SURPASS-PEDS, the first Phase 3 trial to evaluate the safety and efficacy of Mounjaro (tirzepatide), a GIP/GLP-1 dual receptor agonist, in children and adolescents (ages 10 to less than 18) with type 2 diabetes inadequately controlled with metformin, basal insulin or both.

Lilly's Mounjaro (tirzepatide), a GIP/GLP-1 dual receptor agonist, reduced A1C by an average of 2.2% in a Phase 3 trial of children and adolescents with type 2 diabetes

Eli Lilly: New Orforglipron Data In Focus As Commercial Business Outperforms

Eli Lilly and Company's hot streak of obesity and type 2 diabetes readouts ended in early August when we saw underwhelming top-line phase 3 results of orforglipron in obesity patients. Orforglipron looks inferior to oral semaglutide 25mg across trials on weight loss efficacy, but it also beats oral semaglutide 7mg and 14mg in a head-to-head trial. I still see orforglipron as a viable product but am less positive on it after the lower-than-expected efficacy in patients with obesity.

Eli Lilly: New Orforglipron Data In Focus As Commercial Business Outperforms

Zacks Investment Research

LLY's $5B Virginia Plant Plan: Will U.S. Manufacturing Shift Pay Off?

Eli Lilly will invest $5B in a new Virginia plant to make cancer drugs, creating 650 jobs amid Trump's tariff push.

LLY's $5B Virginia Plant Plan: Will U.S. Manufacturing Shift Pay Off?

Bloomberg Markets and Finance

Lilly's GLP-1 Pill Outperforms Older Novo Drug

Patients on Eli Lilly & Co.'s experimental diabetes pill lost more weight and had better blood sugar control than those on an older, approved rival from Novo Nordisk in the first head-to-head trial of the two medicines. Madison Muller reports on "Bloomberg Open Interest.

Lilly's GLP-1 Pill Outperforms Older Novo Drug

Data on Eli Lilly's Weight Loss Pill Hasn't Thrilled Investors. New Updates Are Complicating the Picture.

Data on Eli Lilly's Weight Loss Pill Hasn't Thrilled Investors. New Updates Are Complicating the Picture.

See News Rankings

Charts implemented using Lightweight Charts™